News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal - MedCity News
Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio in 2021. 2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma.
Harnessing Innovative Transplant Diagnostics to Improve Patient Outcomes - MedCity News
Innovative transplant diagnostics and novel paradigms that give a clearer picture of a recipient’s immune system at various phases of the transplant journey can enable transplant teams to mitigate some of these challenges and make more accurate and faster donor assessments, as well as more informed and patient-centric decisions post-transplant.
How Houston Methodist’s ACO Reduced Its End-of-Life Spending by Nearly 20% - MedCity News
Houston Methodist Coordinate Care is reducing costs through a partnership with Koda Health, a digital platform that guides patients through their end-of-life choices. Preliminary findings show the technology resulted in a 19% reduction in the total cost of care for patients at the end of their life, which equals nearly $9,000 in savings per patient.
Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss - MedCity News
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound.
When Dialysis Comes Home, Patients and Care Partners Flourish - MedCity News
When home dialysis is done right, care partners quickly discover they are becoming an integral part of the process as engaged, informed participants rather than uninformed outside observers. By knowing more, care partners can worry a lot less.
Walgreens to Be Acquired by Sycamore Partners: Where Did the Retail Giant Go Wrong? - MedCity News
Walgreens is selling itself to the private equity firm Sycamore Partners. This comes after the company has faced increased competition from online retailers like Amazon. It remains to be seen, however, if Walgreens will perform better under Sycamore Partners.
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market - MedCity News
Beam Therapeutics’ first clinical data in the rare disease alpha-1 antitrypsin deficiency “set a bar for efficacy in the space,” according to one analyst. But the ongoing market slide poses challenges for biotech companies aiming to raise money by selling stock.
Inside Healthcare’s Hottest New AI Category: Agentic AI - MedCity News
Healthcare organizations are starting to implement AI agents — autonomous, task-specific systems designed to perform functions with little or no human intervention. While initial adoption is focused mainly on non-clinical areas like scheduling and prior authorizations, experts predict that AI agents could eventually play a role in clinical decision-making, provided they meet rigorous safety and reliability standards.
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder - MedCity News
Neurotech Pharmaceuticals’ surgically implanted cell and gene therapy, Encelto, is now FDA approved to treat macular telangectasia type 2 (MacTel). It’s the first therapy for this rare retinal degeneration disorder.
Navigating Diagnostic Deserts: How Portable Ultrasound is Improving Maternal Healthcare in Africa - MedCity News
Providing affordable point-of-care diagnostic tools can be instrumental in quickly and efficiently assessing the well-being of all people, especially pregnant mothers. This can empower healthcare providers to be better diagnosticians and improve overall patient care, particularly for those at risk.
Buprenorphine Access Still Lags, Even After Major Federal Policy Changes - MedCity News
While the drop in drug overdose deaths is promising, and could potentially be partially attributed to the efforts of the federal government, we must remain cognizant about the sheer number of lives we continue to lose every year to overdose.
Keys to Provider Patient Communications Amidst President Trump’s Massive Policy Shifts - MedCity News
Exactly what the administration is ultimately able to accomplish will be anyone’s guess, but here are some key policy and market shifts healthcare leaders and their PR teams should watch closely and be prepared to communicate around.
Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy - MedCity News
J&J said aticaprant showed insufficient efficacy in a Phase 3 test in major depressive disorder. The disappointing result follows the Phase 3 failure of a Neumora Therapeutics drug that addresses the same central nervous system target.
This Hospital Exec Wants Nurses to Join the Ambient Listening Party Too - MedCity News
Lavonia Thomas, nursing informatics officer at MD Anderson Cancer Center, hopes that nurses will gain more access to ambient listening tools that listen in on patient conversations and then generate summaries for documentation purposes. These AI tools have become popular among physicians in the past couple years.
A Bright Future for AI in Pharma - MedCity News
The future will see more pharma companies leveraging AI to improve diversity and inclusion, especially in trials that are diverse by design, as well as the odds of finding patients who fit an acceptable set of inclusion/exclusion criteria to accelerate clinical trial timelines.
First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal - MedCity News
Jazz Pharmaceuticals’ acquisition of Chimerix brings a drug that could become the first approved therapy for a rare and aggressive form of brain cancer affecting children and young adults. An FDA decision for the molecule, dordaviprone, is expected in August.
Debunked Episode 13: Will the Real AI Please Stand Up? - MedCity News
The latest episode of Debunked, with MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, talked about the many iterations of AI, NIH funding cuts, and a deal to sell Walgreens.
How High is Too High? The Crippling Cost of Denial Rates - MedCity News
Patients should know exactly what's covered and what it costs before receiving care. Doctors should be empowered to make medical decisions without interference from insurance companies. And the entire process should be designed to facilitate care, not obstruct it.
Novo Nordisk Launches Lower-Cost Wegovy, Following Eli Lilly Into Direct-to-Patient Sales - MedCity News
Wegovy will ship directly to eligible patients through NovoCare, an online pharmacy established by Novo Nordisk. The product’s price matches a recent price cut for Zepbound offered by Eli Lilly through its own direct-to-patient online platform.
Healthcare’s Workforce Blueprint is Out Of Date. It’s Time For A Change - MedCity News
Those that fail to adapt their workforce strategies will remain stuck in crisis mode, scrambling to fill shifts and struggling to retain nurses in the face of a nursing shortage. But for those willing to welcome change, the opportunity is immense.
Bluebird Kids Health Raises $31.5M for Its Value-Based Pediatric Care Clinics in Underserved Areas - MedCity News
Bluebird Kids Health raised $31.5 million in Series A funds. The startup seeks to improve pediatric care access in underserved areas by building practices in these areas and accepting all insurance types.
Data Clean Rooms: The Secret to Secure Healthcare Data Sharing - MedCity News
They allow organizations to break down industry-wide data silos and share data with research partners while maximizing compliance and confidentiality. With the right mindset and implementation, this tech could unlock enormous value for healthcare R&D.